Twist Bioscience Corporation (TWST) is a South San Francisco-based synthetic biology company that writes DNA on silicon chips, supplying genes, oligo pools, antibody libraries, next-generation sequencing panels and protein characterization services to therapeutics, diagnostics and academic customers. On Monday, the stock traded at $103.67, down 7.11% from the prior session's close of $111.60 — a decline of $7.93. The direction was unambiguously lower. The proximate cause was identifiable: a UBS downgrade of its price target to $120 from $190 with a Neutral rating, issued Sunday evening, which landed on top of an already fragile post-earnings tape and a cluster of similar target cuts from other brokers.
The most direct catalyst arrived before Monday's opening bell. UBS lowered its price objective on TWST to $120 from $190, a 37% reduction, while maintaining a Neutral stance. The analyst's reasoning was explicit: the fiscal fourth quarter slightly exceeded expectations and the fiscal 2027 revenue outlook was broadly consistent with consensus, but the bar for a company carrying a premium valuation remains higher than what management delivered.
That note did not land in isolation. Since the Nov. 12 report, a broad set of brokers trimmed targets while mostly retaining constructive ratings — Guggenheim to $150 from $212, TD Cowen to $137 from $190, Jefferies to $125 from $150, Canaccord Genuity to $150 from $205, and Leerink to $175. The pattern matters more than any single number: several firms kept Buy-equivalent ratings yet slashed their implied upside, which forces systematic and momentum-driven holders to re-underwrite positions. When the marginal buyer's valuation anchor drops repeatedly in a compressed window, the equity reprices lower regardless of operating results.
The fundamental root of the de-rating is the fiscal 2027 outlook. TWST guided to revenue of $550 million to $560 million, roughly 21% growth at the midpoint and nominally above consensus. The complication is composition. Management embedded approximately $100 million of AI drug discovery revenue in that range, which equates to about 69% growth — a dramatic step down from the 175% surge to $59.1 million recorded in fiscal 2026. Stripping out AI drug discovery, the base business grows at a mid-teens rate.
Gross margin guidance of 52.5% to 53% also came in below expectations, pressured by roughly $15 million of annualized incremental depreciation tied to a $150 million, two-year capacity program. Investors had been paying for an accelerating AI-linked story; they were handed a decelerating one with heavier capital intensity. The quarter itself was strong — record revenue of $126.6 million, up 28%, 15th consecutive quarter of sequential growth, and positive adjusted EBITDA of $2.2 million for the first time — but the forward math dominated the reaction.
Positioning amplified the move. TWST had rallied more than 250% year-to-date before this stretch, peaking at a $205.00 close on Oct. 5. That advance left the stock priced for sustained triple-digit AI growth, with little tolerance for a guidance reset. The result has been a rolling unwind: five declines in the past six sessions, and a drawdown of approximately 49% from the October peak. High-multiple, narrative-driven biotech tools typically overshoot in both directions, and this sequence fits that profile rather than signaling a change in the underlying franchise.
Turnover has remained heavy since the Nov. 12 report, when more than 2.5 million shares changed hands — roughly double the stock's trailing average of about 1.2 million. Monday's early volume continued at an elevated pace, consistent with institutional repositioning rather than a thin, order-driven move. The selling is company-specific in character: it is tied to Twist's own guidance composition, margin outlook and target revisions rather than to a broad healthcare or index-level shock, and peers in the life-science tools group have not been repriced on the same math.
Technically, the shares are trading well below their 50-day moving average and have erased nearly all of the ground gained during the September–October run. The $111–$114 zone that cushioned Friday's session has now failed, and the psychologically important $100 mark is the next reference point. Momentum indicators are deeply oversold after six weeks of distribution.
The scale runs from 0 — no meaningful news and a move typical for the stock — to 100, representing transformative news paired with an extreme, rare price move. This event scores 33 out of 100. The verified news was moderate: a prominent broker cut its target by 37% and a cluster of peers followed with reductions, all tied to a guidance mix that implies slower AI revenue growth. That is material, but it is a valuation revision rather than an operational shock.
The price move itself was unremarkable by this stock's standards. At 7.11%, Monday's decline was only about 1.4 times the average absolute daily move of roughly 5.2% over the past 80 sessions, and swings of this size or larger occurred 17 times in the last 60 sessions alone. Moderate news plus an ordinary move for a highly volatile name produces a middling score.
Attention shifts to the fiscal 2027 first quarter, with management guiding to revenue of $130 million to $132 million — roughly 26% growth at the midpoint — and to a full year of positive adjusted EBITDA. Management is scheduled to appear at healthcare investor conferences in London and the U.S. this week, giving it an early opportunity to reframe the AI order pipeline, which more than doubled in fiscal 2026, as a leading indicator ahead of reported revenue.
Key swing factors include the pace of capacity additions, with integrated systems rising from 20 to 26 and characterization capacity targeted to expand up to fivefold; early traction for MRD Express and the new X-ray screening antibody offering launched in late October; and whether gross margin can hold near 53% against the depreciation step-up. Risks are concentrated in customer concentration, program timing, the gap between order momentum and recognized revenue, and a valuation that still assumes flawless execution. The next quarterly report, expected in early February, is the next hard checkpoint.
Tickeron's Trending AI Robots page is a curated view of the platform's strongest automated strategies under present market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only the top performers earn a place in this section. Bots differ meaningfully by strategy logic, timeframe, performance metrics and the symbols they trade, so the featured lineup rotates as conditions change. For readers tracking volatile names like this one, it is a practical starting point for comparing systematic approaches — worth a look.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +12.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 63 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.592). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology